

# ACIST Navvus<sup>®</sup> II

## Rapid Exchange FFR MicroCatheter

The freedom to use your choice of guidewire for quick and accurate FFR assessment.

### Product Benefits

#### Enhanced Performance

Featuring **improved flexibility<sup>1</sup>**, **reduced lesion entry profile<sup>2</sup>** and streamlined contouring to allow navigation of complex diseases.

#### Maximize Control

Enables the physician to use **0.014" guidewire of choice** and **maintain wire position** throughout the procedure including pullback and Post PCI assessments.

#### Consistent and Accurate<sup>3</sup>


**Fiber-optic sensor technology** may be less susceptible to drift when compared to traditional pressure wires.<sup>3</sup>

### STREAMLINED CROSSING PROFILE

for Improved Crossability



**15%**<sup>2</sup>  
Reduced Lesion  
Entry Profile



**28%**<sup>1</sup>  
Improved Flexibility




ACIST Navvus II works on any existing RXi or RXi Mini Rapid Exchange FFR System.

**Product and Technical Specifications**

	SKU#016675
Microcatheter length	Overall: 131.9 inches (335 cm), working: 59.1 inches (150 cm)
Rapid exchange distal shaft length	10.2 inches (26 cm)
Operating ambient temperature range	64–86° F (18–30° C)
Operating atmospheric pressure range	11–15 psi, 77–106 kPa
Compatibility	5–8 Fr guiding catheters
Pressure accuracy	±3% of reading or ±3 mmHg of reading over pressure range
Frequency response	Response at 10 Hz within 3 dBA of the response at 1 Hz

**Navvus II**  
SKU #016675

**Navvus**  
SKU #014667



**ACIST Medical Systems, Inc.**

7905 Fuller Road  
Eden Prairie, MN 55344  
USA

[acist.com](http://acist.com)

Tel: +1 888.670.7701  
[customer.support@acist.com](mailto:customer.support@acist.com)

1. TR-07888: Compared with Navvus<sup>®</sup> FFR MicroCatheter in benchtop testing. Data on file at ACIST. May not be indicative of clinical performance.  
2. TR-08707: Compared with Navvus<sup>®</sup> FFR MicroCatheter in benchtop testing. Data on file at ACIST. May not be indicative of clinical performance.  
3. William F. Fearon, Jeffrey W. Chambers, Arnold H. Seto, Ian J. Sarembock, Ganesh Raveendran, Charlotte Sakarovitch, Lingyao Yang, Manisha Desai, Allen Jeremias, and Matthew J. Price and for the ACIST-FFR Study Investigators. Originally published 15 Dec 2017 <https://doi.org/10.1161/CIRCINTERVENTIONS.117.005905> Circulation: Cardiovascular Interventions. 2017;10:e005905

ACIST, ACIST RXi and Navvus are trademarks of ACIST Medical Systems, Inc. ACIST Medical Systems, Inc., reserves the right to modify the specifications and features described herein, or discontinue manufacture of the product described at any time without prior notice or obligation. Please contact your authorized ACIST representative for the most current information.